Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2008-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2008.09.041PMID 18842420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

  2009cited by this paper
• Progress toward a practical BACE-1 inhibitor.

  2007cited by this paper
• Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid.

  2007cited by this paper
• A Century of Alzheimer's Disease

  2006cited by this paper
• Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

  2006cited by this paper
• Progress in the discovery of BACE inhibitors.

  2005cited by this paper
• Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability.

  2005cited by this paper
• Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II.

  2005cited by this paper
• BACE Inhibitors for the Treatment of Alzheimer's Disease

  2005cited by this paper
• Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors.

  2004cited by this paper
• Strategies for disease modification in Alzheimer's disease

  2004cited by this paper
• Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.

  2004cited by this paper
• Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1).

  2004cited by this paper
• Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.

  2004cited by this paper
• Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase.

  2003cited by this paper
• Human β-Secretase (BACE) and BACE Inhibitors

  2003cited by this paper
• Human beta-secretase (BACE) and BACE inhibitors.

  2003cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in?

  2002cited by this paper
• Alzheimer's disease: treatments in discovery and development

  2002cited by this paper
• gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?

  2002cited by this paper
• Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

  2001cited by this paper
• Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).

  2001cited by this paper
• Secretase targets for Alzheimer's disease: identification and therapeutic potential.

  2001cited by this paper
• BACE1 could hold the key to Alzheimer's therapy

  2001cited by this paper
• BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

  2001cited by this paper
• Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.

  2001cited by this paper
• Efficient synthesis of α,β-unsaturated γ-lactones linked to sugars☆

  2001cited by this paper
• Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase)

  2001cited by this paper
• Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation

  2001cited by this paper
• Efficient Intramolecular Glycosylation Supported by a Rigid Spacer

  1999cited by this paper
• HIV-1 protease inhibitors based on acyclic carbohydrates

  1998cited by this paper
• Structurally altered substrates for DNA topoisomerase I. Effects of inclusion of a single 3'-deoxynucleotide within the scissile strand.

  1998cited by this paper
• Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.

  1998cited by this paper
• Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.

  1994cited by this paper
• A free radical route to syn lactones and other prostanoid intermediates in isoprostaglandin synthesis.

  1993cited by this paper
• Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes.

  1991cited by this paper
• Synthesis of Statine and Its Analogues

  1989cited by this paper
• Synthesis of deoxy sugars. Deoxygenation by treatment with N,N'-thiocarbonyldiimidazole/tri-n-butylstannane

  1981cited by this paper

• Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease

  2019cites this paper
• Structure-Based Survey of the Binding Modes of BACE1 Inhibitors.

  2018cites this paper
• Exploring the N-Benzylpiperidine and N. N-Dibenzyl(N-Methyl)amine fragments as privileged structures in the search of new multitarget directed drugs for Alzheimer's disease

  2016cites this paper
• Biological and computational evaluation of resveratrol inhibitors against Alzheimer’s disease

  2016cites this paper
• Total synthesis of a thromboxane receptor antagonist, terutroban.

  2015cites this paper
• On the search for multitarget inhibitors for BACE‐1 and other pharmacological targets of Alzheimer's Disease

  2014cites this paper
• BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.

  2014cites this paper
• Design and Synthesis of Hydroxyethylene-Based BACE-1 Inhibitors Incorporating Extended P 1 Substituents

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

  2014cites this paper
• Design and Synthesis of Hydroxyethylene-Based BACE-1 Inhibitors Incorporating Extended P1 Substituents

  2013influential citation
• Virtual Screening and Structure-Based Discovery of Indole Acylguanidines as Potent β-secretase (BACE1) Inhibitors

  2013cites this paper
• Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

  2013cites this paper
• Design and synthesis of potent hydroxyethylamine (HEA) BACE-1 inhibitors carrying prime side 4,5,6,7-tetrahydrobenzazole and 4,5,6,7-tetrahydropyridinoazole templates.

  2012cites this paper
• Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations.

  2012cites this paper
• Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE)

  2012cites this paper
• Review of synthesis, assay, and prediction of β and γ-secretase inhibitors.

  2012cites this paper
• Synthesis, in vitro Biological Evaluation and Molecular Docking Studies of Benzimidamides as Potential BACE1 Inhibitors

  2012cites this paper
• Highly potent macrocyclic BACE-1 inhibitors incorporating a hydroxyethylamine core: design, synthesis and X-ray crystal structures of enzyme inhibitor complexes.

  2012cites this paper
• Stereochemistry of gamma-amino-beta-hydroxy acids of natural and synthetic origin

  2012cites this paper
• Review of synthesis, biological assay and QSAR studies of β-secretase inhibitors.

  2011cites this paper
• Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution

  2011cites this paper
• Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.

  2010cites this paper
• Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core.

  2010cites this paper
• Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1.

  2010cites this paper
• Design and synthesis of potent and selective BACE-1 inhibitors.

  2010cites this paper
• Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1' alkoxy residues and an aminoethylene (AE) central core.

  2010cites this paper
• Design, synthesis and SAR of a new class of small molecule inhibitors of β-Secretase.

  2010cites this paper
• P2'-truncated BACE-1 inhibitors with a novel hydroxethylene-like core.

  2010cites this paper
• Asymmetric synthesis of anti-aldol segments via a nonaldol route: synthetic applications to statines and (-)-tetrahydrolipstatin.

  2009cites this paper
• Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic.

  2009cites this paper
• alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.

  2009cites this paper
• Substitution of disulphide bonds to hydrophobic amino acids in BACE1

  2009influential citation
• Synthesis and evaluation of a new class of tertiary alcohol based BACE-1 inhibitors

  2009cites this paper